Zum Inhalt springen

TauRx Pharmaceuticals Ltd

LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development

- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities

30.11.2022 20:46

TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results

* Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US …

14.11.2022 08:01

Tau-targeting Alzheimer's treatment, HMTM, moving toward regulatory submission based on initial data from TauRx's LUCIDITY trial

* LUCIDITY data suggest that participants receiving hydromethylthionine mesylate (HMTM) decline at a rate substantially less than is typical in Alzheimer's based on published research

01.06.2022 10:02

TauRx's late-stage clinical trial reaches new milestone

- Significant milestone in the only late-stage clinical trial targeting tau pathology of Alzheimer's

14.04.2022 07:01